PPBT Projected Dividend Yield

ADR (Sponsored) Level 3/Purple Biotech Ltd ( NASDAQ : PPBT )

Purple Biotech is a clinical-stage company developing therapies by overcoming tumor immune evasion and drug resistance. Co.'s segments are: Oncology, which includes CM24, a humanized monoclonal antibody that blocks Carcinoembryonic Antigen Related Cell Adhesion Molecule 1, and NT219, a small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 and Signal Transducer and Activator of Transcription, two signal transduction pathways involved in the development of cancer drug resistance mechanisms; and Pain and Hypertension, which includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension.

20 YEAR PERFORMANCE RESULTS